AML

B2B Gaming Services Taps Sumsub to Provide Top-Notch Upgrade on Customer Onboarding for Betshop

Retrieved on: 
Tuesday, February 6, 2024

LONDON, Feb. 6, 2024 /PRNewswire/ -- Today Sumsub, a global full-cycle verification, anti-fraud and compliance provider, has teamed up with B2B Gaming Services, operator of www.betshop.gr, to streamline KYC (Know Your Customer) procedures and AML monitoring for Betshop.

Key Points: 
  • Sumsub, a global full-cycle verification platform, announces its collaboration with Betshop, one of the most popular iGaming brands in Greece, operated by B2B Gaming Services
    LONDON, Feb. 6, 2024 /PRNewswire/ -- Today Sumsub , a global full-cycle verification, anti-fraud and compliance provider, has teamed up with B2B Gaming Services , operator of www.betshop.gr , to streamline KYC (Know Your Customer) procedures and AML monitoring for Betshop .
  • Within this collaboration, Betshop will integrate Sumsub's solutions into its platform, namely Identity Document Verification, Email & Mobile Risk scoring, AML Screening and Ongoing AML Monitoring, Liveness, Proof of Address (PoA) and Bank Card Verification.
  • "Continuing to invest in strong management systems that support and constantly upgrade the customer experience, B2B GAMING SERVICES (d.b.a www.betshop.gr ) has included among its suppliers the leading provider Sumsub.
  • "Sumsub is happy to start this collaboration with B2B Gaming Services and provide Betshop with our comprehensive solutions specifically tailored to the needs of iGaming platforms," adds Jacob Sever, co-founder and Chief Innovation Officer at Sumsub.

Singular Genomics Unveils G4X™ Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis

Retrieved on: 
Monday, February 5, 2024

The G4X is designed to offer high-throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues.

Key Points: 
  • The G4X is designed to offer high-throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues.
  • The G4X Spatial Sequencer is designed to offer novel capabilities, stackable data streams, and unprecedented throughput for spatial profiling of tissue.
  • Its novel capabilities will include Direct-Seq, which is the sequencing of RNA molecules in situ and has the potential to open new areas of scientific discovery.
  • Singular also plans to provide G4X Spatial Sequencing Technology Access Services starting in the second quarter of 2024.

Tookitaki Announces Rebranding of its AML Suite to FinCense to reflect the enhanced capabilities of the platform

Retrieved on: 
Monday, February 5, 2024

This strategic move is aimed at better representing the enhanced capabilities of its compliance platform, which now seamlessly addresses both fraud and AML risks.

Key Points: 
  • This strategic move is aimed at better representing the enhanced capabilities of its compliance platform, which now seamlessly addresses both fraud and AML risks.
  • The convergence of fraud and AML challenges has reshaped the compliance landscape, leading financial institutions to seek a unified solution.
  • FinCense fosters collaboration between fraud and AML prevention, with a comprehensive platform adept at handling both domains' complexities.
  • FinCense is built for scale by processing billions of transactions with high throughput at 200 TPS for real-time fraud prevention.

Tookitaki Announces Rebranding of its AML Suite to FinCense to reflect the enhanced capabilities of the platform

Retrieved on: 
Monday, February 5, 2024

This strategic move is aimed at better representing the enhanced capabilities of its compliance platform, which now seamlessly addresses both fraud and AML risks.

Key Points: 
  • This strategic move is aimed at better representing the enhanced capabilities of its compliance platform, which now seamlessly addresses both fraud and AML risks.
  • The convergence of fraud and AML challenges has reshaped the compliance landscape, leading financial institutions to seek a unified solution.
  • FinCense fosters collaboration between fraud and AML prevention, with a comprehensive platform adept at handling both domains' complexities.
  • FinCense is built for scale by processing billions of transactions with high throughput at 200 TPS for real-time fraud prevention.

EmTech Invest: FD CAPITAL x GW Capital Hosts Global Economic Symposium in Davos in Collaboration with Stukkert&Co

Retrieved on: 
Thursday, February 1, 2024

Davos, Switzerland--(Newsfile Corp. - February 1, 2024) - EmTech, a prominent technology and business solutions company, hosted a groundbreaking global economic symposium in Davos, Switzerland on January 16 2024.

Key Points: 
  • Davos, Switzerland--(Newsfile Corp. - February 1, 2024) - EmTech, a prominent technology and business solutions company, hosted a groundbreaking global economic symposium in Davos, Switzerland on January 16 2024.
  • The symposium featured keynotes, panel discussions, and interactive sessions that delve into the pressing issues shaping the global economy.
  • (On the left) Mark Minevich - is a Global Visionary that translates vision and strategy into action.
  • This exclusive gathering in 2024 was backed by international investors convened by FD CAPITAL and Swiss digital compliance experts from Green Wealth Capital.

Jason Wingo Joins Coastal Community Bank as Head of BSA/AML Strategy and Solution Management

Retrieved on: 
Friday, February 2, 2024

EVERETT, Wash., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Coastal Financial Corporation (Nasdaq: CCB), the bank holding company for Coastal Community Bank, announced that Jason Wingo has joined the Bank as Senior Vice President, Head of Bank Security Act (BSA) and Anti-Money Laundering (AML) Strategy and Solution Management.

Key Points: 
  • EVERETT, Wash., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Coastal Financial Corporation (Nasdaq: CCB), the bank holding company for Coastal Community Bank, announced that Jason Wingo has joined the Bank as Senior Vice President, Head of Bank Security Act (BSA) and Anti-Money Laundering (AML) Strategy and Solution Management.
  • Mr Wingo is a seasoned IT leader with more than 20 years of experience in multiple platforms, including web-based, client-server, and mainframe.
  • He has extensive experience in requirement gathering, data analysis, development, testing, implementation, and deep expertise in AML, trading compliance, and project management.
  • Wingo received his Bachelor of Science from the University of Missouri and Master of Business Administration from Webster University.

PRISM MarketView Marks World Cancer Day

Retrieved on: 
Thursday, February 1, 2024

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors.

Key Points: 
  • NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors.
  • To mark World Cancer Day , which will be held on February 4, PRISM MarketView highlights emerging companies working to improve the lives of cancer patients and their families by developing and commercializing innovative new treatments for cancer.
  • The company has entered a research agreement with the Johns Hopkins University School of Medicine for the development of Ivospemin.
  • Essa Pharma, a clinical stage pharmaceutical company, is focused on the development of small molecule drugs for the treatment of prostate cancer.

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

Retrieved on: 
Tuesday, January 30, 2024

Continuous daily dosing of ziftomenib at 200 mg QD has been well tolerated and the safety profile consistent with features of underlying disease and backbone therapies.

Key Points: 
  • Continuous daily dosing of ziftomenib at 200 mg QD has been well tolerated and the safety profile consistent with features of underlying disease and backbone therapies.
  • The overall response rate (ORR) among R/R patients treated with ziftomenib and ven/aza was 53% (8/15).
  • As of the data cutoff, 80% (16/20) of patients remain on trial, including 100% (11/11) of all NPM1-m patients.
  • “We are highly encouraged by these preliminary combination data for ziftomenib and believe they support advancement into the frontline AML population,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

CSI Banking Priorities Report: Digital Account Opening, AI, Digital Wallets Emerge as Leading 2024 Initiatives for Community Banks

Retrieved on: 
Thursday, February 1, 2024

“The Banking Priorities report exemplifies the strength, stability and longevity of the community banking market,” said David Culbertson, CEO and president of CSI.

Key Points: 
  • “The Banking Priorities report exemplifies the strength, stability and longevity of the community banking market,” said David Culbertson, CEO and president of CSI.
  • “Seeing financial wellness also ranking highly on bankers’ priorities reinforces a community bank’s opportunity to serve as the epicenter of their community’s financial health.
  • Such priorities reflect an emphasis on overall digital engagement, aligning naturally with digital account opening leading bankers’ technology investments in 2024.
  • “For example, enabling push provisioning within their digital banking platform is a win-win.”
    To access the full report, click here .

2seventy bio Announces New Strategic Path Forward

Retrieved on: 
Tuesday, January 30, 2024

2seventy bio, in partnership with Bristol Myers Squibb (BMS), is taking actions to return Abecma to commercial growth in 2024.

Key Points: 
  • 2seventy bio, in partnership with Bristol Myers Squibb (BMS), is taking actions to return Abecma to commercial growth in 2024.
  • 2seventy bio and BMS are expanding its Abecma site footprint to enable more patients to access the treatment.
  • Upon closing of the transaction with Regeneron, Chip Baird, chief operating officer, will become chief executive officer of 2seventy bio.
  • After 13 years of service on the bluebird bio and 2seventy bio Board of Directors, Dan Lynch will step down from the Board in June and will continue in an advisory role for 2seventy bio.